Taiga Nishihori, MD, discusses the findings from a study evaluating ciltacabtagene autoleucel given in the outpatient setting to patients with relapsed/refractory multiple myeloma. Taiga Nishihori, MD, senior member in the Blood & Marrow Transplant and Cellular Immunotherapy Department at Moffitt Cancer Center, discusses the findings from a single-center, retrospective study...

Outpatient Cilta-cel for Relapsed/Refractory Multiple Myeloma

During a Case-Based Roundtable® event, Andrew Yee, MD, discussed myeloma treatment strategies for different age groups, focusing on personalized regimens and the pros and cons of CAR T-cell therapy and bispecific antibodies in the second article of a 2-part series. Targeted Oncology: Why is achieving a quicker response particularly...

Tailoring Regimens for Different Age Groups With Multiple Myeloma

Suresh S. Ramalingam, MD, discussed the practice-changing findings and implications of the phase 3 LAURA study investigating osimertinib for the treatment of patients with EGFR-mutated non–small cell lung cancer. The phase 3 LAURA study (NCT03521154) showed that the drug osimertinib (Tagrisso) significantly extends survival for patients with unresectable stage...

Osimertinib Offers New Standard of Care in Stage III EGFR-Mutated NSCLC

A high number of adverse events were reported in a late-stage trial conducted by Merck for treatment in lung cancer. Merck announced today that it would be discontinuing its late-stage trial for vibostolimab/pembrolizumab plus chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC).1 The anti–PD-1 therapy was being compared with atezolizumab in combination with chemotherapy in the KeyVibe-008 trial (NCT05224141). However, patients on vibostolimab/pembrolizumab had a higher rate of adverse events (AEs) and immune-related AEs compared with the control arm, leading to its discontinuation.

Late-Stage Vibostolimab, Pembrolizumab Plus Chemotherapy Trial Discontinued Due to Adverse Events

In an interview with Targeted Oncology, John Mascarenhas, MD, discussed the lead up to the SENTRY trial and its potential impact on the treatment of myelofibrosis. The myelofibrosis treatment landscape is moving to one where combination therapy may likely become the standard of care. However, more research is needed as there currently are no approved Janus kinase (JAK) inhibitors with novel agents in this space.

Emerging Era of Combination Therapy in Myelofibrosis Explored in SENTRY Study

I decided to receive CAR-T cell therapy for multiple myeloma when my previous regimen stopped working and now, I'm living my best life. Following an infection that was resistant to treatment and a few “extra” blood tests, the doctor advised me to see a hematologist (that was OK!) or an oncologist (not so good to hear). In January 2007, the diagnosis of multiple myeloma was followed by several “new normals” for my family and me.

My Decision to Receive CAR-T Cell Therapy for Multiple Myeloma

The National Comprehensive Cancer Network now recommends Rytelo for patients with myelodysplastic syndrome who require blood transfusions. The National Comprehensive Cancer Network (NCCN) now recommends Rytelo (imetelstat) as a treatment for patients with lower-risk myelodysplastic syndrome (MDS) who have symptomatic anemia. The NCCN is comprised of leading oncology centers. They...

NCCN Recommends Rytelo for Anemia in Patients With MDS

A multicenter, randomized, double-blind, placebo-controlled trial done performed in the the United Kingdom June 2014 to October 2017), enrolled 207 adult patients with symptomatic, radiographic KOA and knee pain (severity ≥4 out of 10) on most days in the past 3 months, after an inadequate response to analgesic medications.

Pain Reduction with Methotrexate in Knee Osteoarthritis

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. It can progress slowly and may not cause many symptoms. Although it is treatable, it’s not considered to be curable. In the early stages, CLL often doesn't require treatment immediately, as studies have...

Chronic Lymphocytic Leukemia (CLL): When to Treat Cancer or Hold Off

Ferritin cutoffs of 30 and 45 ng/mL notably increase the rate of iron deficiency diagnoses. Guideline-recommended cutoffs for serum ferritin were linked to the incidence of iron deficiency diagnoses in primary care, according to a recent retrospective cohort study in JAMA Network Open.1. Across more than 255,000 adult primary care...

Ferritin Cutoff Choice Linked to Rates of Iron Deficiency Diagnosis

In 1972, Janet Rowley sat at her dining room table and cut tiny chromosomes from photographs she had taken in her laboratory. One by one, she snipped out the small figures her children teasingly called paper dolls. She then carefully laid them out in 23 matching pairs—and warned her kids not to sneeze.

Path to precision: Targeted cancer drugs go from table to trials to bedside

WEDNESDAY, Aug. 7, 2024 (HealthDay News) — The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma (MM) who are eligible for an autologous stem cell transplant (ASCT).

FDA Approves Darzalex Faspro for Treating Multiple Myeloma

Anemia is common in high-risk PCI and is independently associated with major adverse cardiovascular events and major bleeding risk. Baseline anemia is frequently identified in patients undergoing Impella-supported high-risk percutaneous coronary intervention (HRPCI), according to the results of a recent post hoc analysis of the PROTECT III study.1. The presence...

Anemia Linked to Adverse Outcomes After Percutaneous Coronary Intervention

Study shows patients 80 years and older with atrial fibrillation treated with a lower dose of edoxaban experienced fewer major gastrointestinal bleeding events for each additional ischemic stroke. Patients aged 80 years and above with atrial fibrillation (AF) may gain a benefit from treatment with lower-dose anticoagulants regardless of existing...

Phase III Trial Shows Older Patients with Atrial Fibrillation May Benefit From Lower-Dose Anticoagulants

NCCN guidelines have been updated to recommend imetelstat to treat symptomatic anemia in patients with lower-risk myelodysplastic syndromes. The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines in oncology to now recommend imetelstat (Rytelo) as a Category 1 and 2A treatment for symptomatic anemia in patients with lower-risk myelodysplastic syndromes (MDS).1.

Updated NCCN Guidelines Recommend Imetelstat to Treat Anemia in Lower-Risk MDS

Researchers have demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy may improve progression-free survival in patients with oligometastatic pancreatic cancer, according to a recent study published by Ludmir et al in the Journal of Clinical Oncology and previously presented at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract 603). Background.

Metastasis-Directed Radiation Therapy Plus Chemotherapy in Oligometastatic Pancreatic Cancer

Approval marks the first time an immuno-oncology regimen has demonstrated a survival benefit for all adults with primary advanced or recurrent endometrial cancer, company says. The FDA has approved an expanded indication for GSK’s Jemperli (dostarlimab) to include treatment of all adults with primary advanced or recurrent endometrial cancer. According...

FDA Expands Approval of GSK’s Jemperli in Combination with Chemotherapy for Adults with Primary Advanced or Recurrent Endometrial Cancer

Reuters

(Reuters) - Servier Pharmaceuticals said on Tuesday the U.S. Food and Drug administration has approved the French drugmaker's treatment for a type of brain tumor, making it the first drug to get a U.S. approval for the condition.

US FDA approves Servier's brain tumor treatment

Surgery isn’t a typical treatment for multiple myeloma. But in some cases, surgery may be necessary to address complications from the disease. Multiple myeloma is a rare type of cancer that causes abnormal cells to develop in your bone marrow. As multiple myeloma spreads, it can lead to bone damage or loss.

The Role of Surgery in Treating Multiple Myeloma

Chicago, IL

Writers represent independent, third-party users who have joined our contributor program and self-verified their accounts. Writers are expected, like all users, to adhere to our Community Standards.

writer

Foodie in Chicago

Shortly before 3 AM, people in the Chicago area may have felt their houses shake as a 3.4-magnitude earthquake occurred about 60 miles west of the city. (CHICAGO) The United States Geological Survey (USGS) reported a 3.4-magnitude earthquake around Somonauk, IL. Somonauk is in DeKalb and LaSalle Counties, 64 miles west of Chicago.

Did You Feel the Earthquake?

NewsBreak

Isa-VRd Significantly Improves Survival vs VRd in Transplant-Eligible Myeloma

Isatuximab plus VRd induction before transplant led to better progression-free survival compared with VRd alone, according to data from the GMMG-HD7 phase 3 study. The addition...

Isa-VRd Significantly Improves Survival vs VRd in Transplant-Eligible Myeloma

Comments / 0